TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes

BACKGROUND: Lung squamous cell carcinoma (LUSC) is characterized by frequent mutations of tumor protein p53 (TP53) and cyclin dependent kinase inhibitor 2A (CDKN2A). However, to date, the impact of TP53/CDKN2A status on the clinical outcome of patients with early-stage LUSC is unclear. METHODS: Tiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Peiyuan, Wang, Feng, He, Hao, Chen, Yujie, Lin, Hui, Chen, Peng, Chen, Xiaofeng, Liu, Shuoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422115/
https://www.ncbi.nlm.nih.gov/pubmed/34532467
http://dx.doi.org/10.21037/atm-21-3709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422115/
https://www.ncbi.nlm.nih.gov/pubmed/34532467
http://dx.doi.org/10.21037/atm-21-3709

Ejemplares similares